TY - JOUR T1 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1136/jitc-2020-001235 VL - 8 IS - 2 SP - e001235 AU - Sattva S Neelapu AU - Sherry Adkins AU - Stephen M Ansell AU - Joshua Brody AU - Mitchell S Cairo AU - Jonathan W Friedberg AU - Justin P Kline AU - Ronald Levy AU - David L Porter AU - Koen van Besien AU - Michael Werner AU - Michael R Bishop Y1 - 2020/12/01 UR - http://jitc.bmj.com/content/8/2/e001235.abstract N2 - The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma. ER -